Nicholas Iafe, MD
Retina Specialist · Brentwood, MONPI 1942733811
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Eyepoint US, Inc. at 33.2% of the total.
Across 108 payments — averaging $85.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$3K
- Carl Zeiss Meditec USA, Inc.$2K
- AbbVie$1K
- Dutch Ophthalmic, USA$953
- Genentech USA, Inc.$591
- Regeneron Healthcare Solutions, Inc.$438
- plus $1K from 7 others
What the payments were for
- Consulting fees$2,75030%
- Travel & lodging$1,49516%
- Food & beverage$4,97854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 5 | $3,057 |
| Carl Zeiss Meditec USA, Inc. | 10 | $1,990 |
| AbbVie(2 entities) | 34 | $1,148 |
| Dutch Ophthalmic, USA | 7 | $953 |
| Genentech USA, Inc. | 18 | $591 |
| Regeneron Healthcare Solutions, Inc. | 10 | $438 |
| Alcon | 4 | $326 |
| Astellas Pharma US Inc | 10 | $267 |
| Apellis Pharmaceuticals, Inc. | 2 | $143 |
| Genentech, Inc. | 1 | $141 |
| Bausch & Lomb Americas Inc. | 3 | $66 |
| ANI Pharmaceuticals, Inc. | 2 | $61 |
| Alimera Sciences, Inc. | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYP-1901$2,018
- YUTIQ$1,023
- EVA, combined machine$714
- TISSUEBLUE$714
- OZURDEX$475
- VABYSMO$274
- EVA Ophthalmic Surgical System$158
- AcrySof$138
- EYLEA$125
- Syfovre$118
How this compares
$9,222 in reported general payments places this provider in the 75th percentile of 45 retina specialist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 229 | $8,770 |
| Bromfenac Sodium | 27 | $4,183 |
| Ketorolac Tromethamine | 192 | $3,620 |
| Difluprednate | 16 | $2,050 |
| MoxifloxacinMoxifloxacin Hcl | 84 | $1,712 |
| Atropine Sulfate | 42 | $1,565 |
| Brimonidine Tartrate | 48 | $1,335 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $361 |
| Dorzolamide Hcl | 29 | $339 |
| Latanoprost | 30 | $220 |
| Ofloxacin | 17 | $160 |
| Timolol Maleate | 27 | $102 |
| Diclofenac Sodium | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Brentwood
- Kevin BlinderBrentwood$333K
- Sabin DangBrentwood$174K
- Athanasios PapakostasBrentwood$85K
- Alia DurraniBrentwood$53K
- Barton BlackorbyBrentwood$31K
- Ollya FromalBrentwood$14K
- Dillan PatelBrentwood$5K
- Bradley SmithBrentwood$5K
- William AndersonBrentwood$4K
- Prithvi BomdicaBrentwood$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.